Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03288571Phase 1Unknown

Use of Wharton Jelly in Diabetic Nephropathy

Role: lead

NCT03297814Phase 1Unknown

Use of Allogenic Platelet Lysate in Peripheral Arterial Disease (PAD)

Role: lead

NCT03066245Phase 1Unknown

Use of Stem Cells Cultured on a Scaffold for the Treatment of Aneurysmal Bone Cysts (ABC)

Role: lead

NCT02940418Phase 1Unknown

Use of Stem Cells in Diabetes Mellitus Type 1

Role: lead

NCT03751735Phase 1Completed

Efficacy of Wharton Jelly in Erectile Dysfunction

Role: lead

NCT02945449Phase 1Completed

Safety of Wharton Jelly in Erectile Dysfunction

Role: lead

All 6 trials loaded